Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on MRNS. Royal Bank of Canada decreased their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a report on Friday, October 25th. Jefferies Financial Group reissued a “hold” rating and set a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. HC Wainwright reissued a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, JMP Securities reissued a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Down 0.2 %

Shares of Marinus Pharmaceuticals stock opened at $0.55 on Friday. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $10.50. The stock’s fifty day moving average is $0.45 and its 200 day moving average is $0.89.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MRNS. AQR Capital Management LLC increased its stake in Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Marinus Pharmaceuticals by 70.3% during the third quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock worth $782,000 after acquiring an additional 183,396 shares during the last quarter. abrdn plc increased its stake in Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after acquiring an additional 1,578,329 shares during the last quarter. GSA Capital Partners LLP increased its stake in Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after acquiring an additional 817,050 shares during the last quarter. Finally, Suvretta Capital Management LLC increased its stake in Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the last quarter. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.